ACRP, ENACCT Partner on Cancer Trials Recruitment Professional Education
ACRP and ENACCT announced the integration of key ENACCT products and services into the current ACRP professional development portfolio.
The Association of Clinical Research Professionals (ACRP) and the Education Network to Advance Cancer Clinical Trials (ENACCT) announced the integration of key ENACCT products and services into the current ACRP professional development portfolio.
The integration is another step in ACRP's commitment to expand its educational programs and services to enhance the skills of clinical research professionals. Developed over the last 10 years by national experts in the field, the ENACCT programs and services focus on increasing cancer clinical trial participation, particularly within underserved communities. ACRP and ENACCT's integration will see products and services offered by ENACCT transferred to ACRP, which will host these cancer-focused resources among its professional development catalog. ENACCT's integration will allow the formation of a new Clinical Trials Recruitment Interest Group that will allow members to actively engage in open dialogue about challenges and solutions pertinent to this topic.
ACRP will pursue additional resources for creating new and updated content to further serve the interests of the former ENACCT membership and current ACRP community regarding clinical trials accrual and cancer clinical research.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
